“Phase 3 Trial Finds Full-Spectrum Cannabis Extract VER-01 Provides Clinically Significant Relief for Chronic Low Back Pain with Improved Safety Profile”

The recent comprehensive data from a large, phase 3 randomized controlled trial provide promising evidence that a full-spectrum cannabis extract, VER-01, is effective and well-tolerated for chronic low back pain (CLBP), a widespread and debilitating condition affecting over 600 million people globally. The results, published in the reputable journal Nature Medicine and reported by multiple credible medical news sources in late September 2025, offer a potential new treatment option that could significantly impact public health by addressing pain with fewer risks than opioids or long-term NSAIDs.

Key Findings from the Phase 3 Trial

The trial involved 820 adults with chronic low back pain who had insufficient relief from standard non-opioid therapies. Participants were randomized to receive either VER-01, a full-spectrum cannabis extract derived from Cannabis sativa DKJ127, or a placebo formulated to match the cannabis extract’s appearance and sensory properties. Over 12 weeks, those treated with VER-01 achieved a mean pain reduction of 1.9 points on the numeric rating scale (NRS), compared to a 0.6-point reduction in the placebo group (scale 0-10, with 10 representing worst pain). This difference represents a clinically meaningful improvement in pain intensity for those receiving the cannabis extract.​

An open-label extension phase following the randomized trial showed continued improvement, with mean pain scores in the treated group decreasing further to 2.9 points below baseline over six months. The study’s size, rigorous design, and duration lend significant weight to these findings, distinguishing this research from prior smaller or lower-quality studies of cannabis for chronic pain relief.​

Expert Perspectives

Dr. Jan Vollert, a neuroscience lecturer at the University of Exeter, lauded the study as an important step forward. He emphasized that this trial provides high-quality evidence of clinically meaningful pain relief, surpassing prior inconsistent cannabis research results. Dr. Vollert highlighted that while the results are promising, further studies are still needed to confirm the sustainability of the benefits observed, particularly in longer-term randomized withdrawal phases.​

Experts also clarified that VER-01 is a precise, pharmaceutical-grade cannabis extract quite different from smoked cannabis, which carries other risks and variable effects. This distinction is critical for patients and clinicians considering medical cannabis as a therapeutic agent.​

Background and Context

Chronic low back pain is the leading cause of disability worldwide, often resistant to conventional treatments. Existing medications like opioids pose addiction risks, and nonsteroidal anti-inflammatory drugs (NSAIDs) may introduce cardiovascular or gastrointestinal complications when used long-term. This leaves a gap for new treatments that effectively relieve pain with safer profiles.​

Cannabis has been researched extensively for chronic pain, with several observational and smaller trials suggesting modest benefits. The active compounds THC and CBD modulate the body’s endocannabinoid system, which regulates pain perception, inflammation, mood, and sleep. Full-spectrum cannabis extracts contain multiple cannabinoids and terpenes thought to work synergistically to enhance therapeutic effects.​

Public Health Implications

The significant analgesic effect observed in this large trial supports VER-01 as a promising new treatment for patients suffering chronic low back pain who have not responded adequately to existing therapies. Compared to opioids, cannabis extracts may offer pain relief with a lower risk of dependency and serious adverse effects, making it a potentially safer alternative for long-term management.​

Improved pain control can also enhance patients’ physical functioning and mental well-being, addressing the broader consequences of chronic pain such as depression and sleep disturbances. However, medical cannabis use should follow clinical guidance, ensuring proper dosing and monitoring for side effects such as dizziness or sleepiness.​

Limitations and Considerations

While the trial demonstrates efficacy and a favorable safety profile, the authors and experts caution that this is one study. More research is essential to understand long-term effects, optimal dosing regimens, and how cannabis extracts compare directly with other pain treatments across diverse patient groups.

The lack of significance in certain trial phases, such as randomized withdrawal, indicates a need for further investigation to assess whether pain relief persists after stopping the treatment. Moreover, cannabis is not universally effective; some patients might not respond, underscoring the importance of individualized medical consultation.​

Conclusion

This landmark phase 3 trial of VER-01, a full-spectrum cannabis extract, represents a significant advancement in the treatment landscape for chronic low back pain. The findings provide strong evidence supporting its efficacy and safety, offering hope for millions affected by this chronic condition. As research continues, patients and healthcare professionals will benefit from clearer guidance on integrating medical cannabis into comprehensive pain management strategies.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References